Halozyme Therapeutics Inc. has entered into a global collaboration and exclusive license agreement with Takeda, which provides Takeda with access to Halozyme’s ENHANZE drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20), for use with vedolizumab (marketed globally as ENTYVIO).

ENTYVIO is approved for use in adults with moderately to severely active Crohn’s disease or ulcerative colitis.

Under the terms of the agreement, Takeda will make an upfront payment to Halozyme, and potential future development and commercial milestone payments. Halozyme will also be entitled to up to low-mid single digit royalties on sales of products containing vedolizumab in combination with ENHANZE.

Halozyme, Takeda Leadership Reacts

“Our collaboration with Takeda reflects our ongoing commitment to delivering innovative solutions that enhance the patient experience, with the goal of helping patients spend less time managing their therapy and more time living their lives,” said Dr. Helen Torley, President and CEO of Halozyme. “Our new collaboration reinforces the broad applicability and value of the ENHANZE technology across multiple therapeutic areas.”

“People living with ulcerative colitis and Crohn’s disease, as well as their health care providers, need flexible treatment options that match evolving needs and priorities in disease management,” said Robert Hollowell, M.D., Head of Global Product and Launch Strategy, GI and Inflammation at Takeda. “Our collaboration is another example of our commitment to the IBD community and leadership in this therapeutic area. It is an exciting opportunity to potentially enable vedolizumab to benefit even more patients around the world, and integrate even more seamlessly into patients’ lives.”

The Latest from Takeda

In December, Takeda joined BaseLaunch, a platform created to launch, fund, and build early biotech ventures developing cutting-edge therapeutics.